RETIFANLIMAB VS AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: A COST-UTILITY ANALYSIS IN ITALY

被引：0
|
作者：
Ghetti, G. [1 ]
Porta, C. [1 ]
Povero, M. [1 ]
Trimarchi, C. [2 ]
机构：
[1] AdRes HE, Turin, Italy
[2] Incyte Biosci Italy, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE65
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [31] Avelumab treatment in chemotherapy-naive patients with distant metastatic Merkel cell carcinoma (mMCC)
    D'Angelo, S. P.
    Russell, J.
    Hassel, J.
    Lebbe, C.
    Chmielowski, B.
    Rabinowits, G.
    Terheyden, P.
    Brownell, I.
    Zwiener, I.
    Bajars, M.
    Hennessy, M.
    Kaufman, H. L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Two Clinical Cases of Metastatic Merkel Cell Carcinoma Illustrating Avelumab Tolerability in Elderly Patients
    Josephs, Bridget
    Sewak, Sanjeev
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (06) : 599 - 602
  • [33] Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.
    Kaufman, Howard L.
    Russell, Jeffrey
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    von Heydebreck, Anja
    Mahnke, Lisa
    Nghiem, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [34] Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.
    Shapiro, Irina
    Grote, Hans Juergen
    D'Urso, Vittorio
    von Heydebreck, Anja
    Mahnke, Lisa
    Kaufman, Howard
    Nghiem, Paul
    Cal, Ti
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
    Gaiser, Maria Rita
    Bongiorno, Michelle
    Brownell, Isaac
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 345 - 359
  • [36] Rapid Response of a multilocular metastatic Merkel Cell Carcinoma with an unclear Primarius to Avelumab
    Bender-Saebelkampf, S.
    Berking, C.
    Erdmann, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 46 - 46
  • [37] Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
    Glutsch, V.
    Kneitz, H.
    Goebeler, M.
    Gesierich, A.
    Schilling, B.
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1667 - 1668
  • [38] Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
    Min, Sandy Tun
    Nordman, Ina I. C.
    Tran, Huy A.
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 639 - 643
  • [39] COST-UTILITY ANALYSIS FOR METASTATIC MERKEL CELL CARCINOMA (MMCC) TREATMENT IN TAIWAN: ADAPTING A GLOBAL MODEL FOR AN ULTRA-RARE LIFE-THREATENING DISEASE
    Palencia, R.
    Hsu, J. C.
    Lin, A. Y.
    Goh, C.
    Chang, H. C.
    Chou, P.
    Kuo, K.
    Chang, W. C.
    VALUE IN HEALTH, 2020, 23 : S43 - S43
  • [40] Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
    Giovanni Grignani
    Vanna Chiarion Sileni
    Carmine Pinto
    Roberta Depenni
    Nicola Fazio
    Luca Galli
    Dario Giuffrida
    Carlo Carnaghi
    Domenico Ciliberto
    Domenico C. Corsi
    Paola Queirolo
    Elena Benincasa
    Filippo Venturini
    Gennaro Fazzi
    Nuno Costa
    Paolo Antonio Ascierto
    Journal of Translational Medicine, 19
12345